BRAF inhibitor-induced panniculitis appearance on 18F-FDG PET/CT

Stephen M. Broski; Erin K. Moran; Katrina N. Glazebrook; Mark A. Nathan

doi:10.1097/RLU.0000000000001027

BRAF inhibitor-induced panniculitis appearance on ¹⁸F-FDG PET/CT

Stephen M. Broski, Erin K. Moran, Katrina N. Glazebrook, Mark A. Nathan

Radiology

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

BRAF inhibitors vemurafenib and dabrafenib have become the standard of care for treatment of stage IV metastatic melanoma harboring a BRAF mutation. Panniculitis is a rare but known adverse side effect of these agents and presents with tender erythematous nodules. These nodules may demonstrate uptake on ¹⁸F-FDG PET/CT, whichmay mimic metastatic disease in patients undergoing treatment. We present a case of BRAF inhibitor-induced panniculitis in a patient with stage IV metastatic melanoma and discuss the imaging findings on ¹⁸F-FDG PET/CT.

Original language	English (US)
Pages (from-to)	e149-e151
Journal	Clinical nuclear medicine
Volume	41
Issue number	3
DOIs	https://doi.org/10.1097/RLU.0000000000001027
State	Published - 2016

Keywords

BRAF
FDG
PET/CT
Panniculitis

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1097/RLU.0000000000001027

Cite this

@article{9350b255ee2c483d88f9d2db2410c8ed,

title = "BRAF inhibitor-induced panniculitis appearance on 18F-FDG PET/CT",

abstract = "BRAF inhibitors vemurafenib and dabrafenib have become the standard of care for treatment of stage IV metastatic melanoma harboring a BRAF mutation. Panniculitis is a rare but known adverse side effect of these agents and presents with tender erythematous nodules. These nodules may demonstrate uptake on 18F-FDG PET/CT, whichmay mimic metastatic disease in patients undergoing treatment. We present a case of BRAF inhibitor-induced panniculitis in a patient with stage IV metastatic melanoma and discuss the imaging findings on 18F-FDG PET/CT.",

keywords = "BRAF, FDG, PET/CT, Panniculitis",

author = "Broski, {Stephen M.} and Moran, {Erin K.} and Glazebrook, {Katrina N.} and Nathan, {Mark A.}",

year = "2016",

doi = "10.1097/RLU.0000000000001027",

language = "English (US)",

volume = "41",

pages = "e149--e151",

journal = "Clinical nuclear medicine",

issn = "0363-9762",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - BRAF inhibitor-induced panniculitis appearance on 18F-FDG PET/CT

AU - Broski, Stephen M.

AU - Moran, Erin K.

AU - Glazebrook, Katrina N.

AU - Nathan, Mark A.

PY - 2016

Y1 - 2016

N2 - BRAF inhibitors vemurafenib and dabrafenib have become the standard of care for treatment of stage IV metastatic melanoma harboring a BRAF mutation. Panniculitis is a rare but known adverse side effect of these agents and presents with tender erythematous nodules. These nodules may demonstrate uptake on 18F-FDG PET/CT, whichmay mimic metastatic disease in patients undergoing treatment. We present a case of BRAF inhibitor-induced panniculitis in a patient with stage IV metastatic melanoma and discuss the imaging findings on 18F-FDG PET/CT.

AB - BRAF inhibitors vemurafenib and dabrafenib have become the standard of care for treatment of stage IV metastatic melanoma harboring a BRAF mutation. Panniculitis is a rare but known adverse side effect of these agents and presents with tender erythematous nodules. These nodules may demonstrate uptake on 18F-FDG PET/CT, whichmay mimic metastatic disease in patients undergoing treatment. We present a case of BRAF inhibitor-induced panniculitis in a patient with stage IV metastatic melanoma and discuss the imaging findings on 18F-FDG PET/CT.

KW - BRAF

KW - FDG

KW - PET/CT

KW - Panniculitis

UR - http://www.scopus.com/inward/record.url?scp=84944345258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944345258&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000001027

DO - 10.1097/RLU.0000000000001027

M3 - Article

C2 - 26447389

AN - SCOPUS:84944345258

SN - 0363-9762

VL - 41

SP - e149-e151

JO - Clinical nuclear medicine

JF - Clinical nuclear medicine

IS - 3

ER -